Want to join the conversation?
Biopharmaceutical major $BXLT reported a 14% jump in 1Q16 revenue, but quarterly profit fell on higher costs. The company, focused on hemophilia treatment, reported earnings of $145MM, or $0.21 per share, down from $272MM, or $0.38 per share a year ago. Revenue rose to $1.55Bil. Expenses rose by 36%.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.